drugset / Trial / NCT02445794
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of RT001 in patients with Friedreich's ataxia.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-06
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RT001 | Protein / enzyme biologic | 1.8 g | Oral |
| Subject | linoleic acid ethyl ester | Unknown | 9 g | Oral |